AI-generated analysis. Always verify with the original filing.
Allarity Therapeutics reported a reduced net loss of $11.2 million for FY 2025 and strengthened its balance sheet with a $20 million debt financing in March 2026, extending cash runway to mid-2028.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition.** On March 31, 2026, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing its financial
Financial Statements and Exhibits.** (d) Exhibits. | Exhibit Number | | Description | |---|---|---| | 99.1 | | Press Release, dated March 31, 2026. | | 104 | |
| Metric | Value | Basis |
|---|---|---|
| Revenue | $0.32 | |
| R&D Expenses | $6.60 | GAAP |
| G&A Expenses | $6.30 | GAAP |
| Net Loss | $11.20 | GAAP |
| Net Loss Per Share | $0.78 | GAAP |
Debt / Financing